Actively Recruiting
Evaluating 18F68GaGP1 PETCT Imaging for Thrombi Detection and Diagnosis
Led by Tianjin Medical University · Updated on 2026-09-10
500
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of a specialized PET imaging tracer called 18F68GaGP1 to visualize abnormal tau pathology and thrombi-related diseases in the living human brain. This study focuses on assessing the safety and diagnostic effectiveness of this tracer in adults with suspected or diagnosed thrombi conditions. The investigation is part of ongoing efforts worldwide to develop and validate GPIIbIIIa imaging agents. Participants receive a single intravenous injection of 10 3 mCi of 18F68GaGP1, followed by a PETCT scan to observe the tracers distribution and binding in the body. The study includes both healthy individuals and patients with thrombi. Imaging may also involve MRI as part of the evaluation process. Throughout the study, participants are involved in one-time imaging procedures after tracer injection. Researchers measure the standardized uptake value SUV within 30 days to assess tracer uptake. Diagnostic effectiveness is also evaluated within the same period. Participants provide informed consent before enrollment, and the study monitors safety and imaging outcomes over the course of the trial.
CONDITIONS
Brief Title
Glycoprotein IIb/IIIa PET/CT in Various GPIIb/IIIa-Related Disease
Research Team
H
Haonan Yu, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here